Cox regression on EBV-related complications
Factor . | Relative risk (95% CI) . | P . |
|---|---|---|
| Conditioning | ||
| Myeloablative* | 1.0 | |
| Nonmyeloablative, without ATG | 0.7 (0.1-6.5) | .51 |
| Nonmyeloablative, with ATG | 15.4 (2.0-116.1) | <.01 |
| CMV serostatus | ||
| Positive* | 1.0 | |
| Negative | 3.0 (0.9-9.7) | .07 |
| HLA, engrafted in doubles | ||
| 6 of 6 | 1.0 | |
| 5 of 6 | 0.2 (0.1-1.5) | .12 |
| 3-4 of 6 | 0.9 (0.2-4.7) | .94 |
| No. of donors | ||
| 1 | 1.0 | |
| 2 | 0.4 (0.1-2.4) | .29 |
Factor . | Relative risk (95% CI) . | P . |
|---|---|---|
| Conditioning | ||
| Myeloablative* | 1.0 | |
| Nonmyeloablative, without ATG | 0.7 (0.1-6.5) | .51 |
| Nonmyeloablative, with ATG | 15.4 (2.0-116.1) | <.01 |
| CMV serostatus | ||
| Positive* | 1.0 | |
| Negative | 3.0 (0.9-9.7) | .07 |
| HLA, engrafted in doubles | ||
| 6 of 6 | 1.0 | |
| 5 of 6 | 0.2 (0.1-1.5) | .12 |
| 3-4 of 6 | 0.9 (0.2-4.7) | .94 |
| No. of donors | ||
| 1 | 1.0 | |
| 2 | 0.4 (0.1-2.4) | .29 |
Factors included in the model and tested for proportional hazards were conditioning regimen, CMV serostatus, age, weight, graft-versus-host disease prophylaxis, cell dose, diagnosis, number of UCB donor units, HLA match, prior autologous transplant, and sex
CI indicates confidence interval; ATG, antithymocyte globulin; and CMV, cytomegalovirus